{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:44:55Z","timestamp":1790783095202,"version":"4.1.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of these emerging agents. A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults. Clinical outcomes were assessed using the random\u2010effects model and pooled as mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs). A total of 10 randomized controlled trials, including 3236 participants, were analyzed. Incretin polyagonists significantly reduced body weight compared to placebo (MD \u221211.47; 95% CI: \u221214.00 to \u22128.95). Significant reductions were also observed in waist circumference (MD \u22129.40; 95% CI: \u221211.91 to \u22126.89), glycated hemoglobin (MD \u22120.96; 95% CI: \u22121.16 to \u22120.75), and fasting plasma glucose (MD \u221226.89\u2009mg\/dL; 95% CI: \u221233.48 to \u221220.30). However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08\u20131.19), including gastrointestinal AEs (nausea, vomiting, diarrhea, constipation), AEs leading to withdrawal (RR 1.96; 95% CI: 1.17\u20133.30), and hypoglycemic episodes (RR 3.08; 95% CI: 1.61\u20135.89). No significant difference was found in serious AEs (RR 0.87; 95% CI: 0.65\u20131.14). In conclusion, incretin-based polyagonists were associated with significant weight reduction and improved metabolic outcomes compared to placebo.<\/jats:p>","DOI":"10.1097\/crd.0000000000001209","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:00:09Z","timestamp":1771513209000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","author":[{"given":"Zhi Hong","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Musgrove Park Hospital, Somerset, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdousamad Said","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Aneurin Bevan University Health Board, Newport, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Gill","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Volucke","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Muneeb","family":"Azhar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mukhtar A. Sheikh Hospital, Multan, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mohammad","family":"Haleem","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aria Institute of Medical Sciences, Quetta, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian En","family":"Sia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid Ur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sandwell and West Birmingham NHS Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaz","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Rotherham NHS Foundation Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuraan","family":"Shahid","sequence":"additional","affiliation":[{"name":"Department of Radiology, James Cook University Hospital, Middlesbrough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Anjum","family":"Gardezi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Johns Hopkins Healthcare Aramco, Eastern Province. Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Vinod","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aria Institute of Medical Sciences, Quetta, Pakistan"},{"name":"Department of Medicine, Addenbrooke\u2019s Hospital, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitish","family":"Behary Paray","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Somerset NHS Foundation Trust, Taunton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeshal","family":"Zulfiqar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"R1-20260219","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis.","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"R2-20260219","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/jdi.14386","article-title":"Rising mortality rates linked to type\u20102 diabetes and obesity in the United States: an observational analysis from 1999 to 2022.","volume":"16","author":"Ahmed","year":"2024","journal-title":"J Diabetes Investig"},{"key":"R3-20260219","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity.","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"issue":"Suppl 2","key":"R5-20260219","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.16263","article-title":"An overview of obesity-related complications: the epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.","volume":"27","author":"Bl\u00fcher","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R6-20260219","doi-asserted-by":"crossref","first-page":"706978","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: epidemiology, pathophysiology, and therapeutics.","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol"},{"key":"R7-20260219","doi-asserted-by":"crossref","first-page":"e70010","DOI":"10.1002\/edm2.70010","article-title":"Trends and disparities in coronary artery disease and obesity-related mortality in the United States From 1999-2022.","volume":"7","author":"Ahmed","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"key":"R8-20260219","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.jacadv.2025.101882","article-title":"Type 2 diabetes mellitus-related mortality in the United States, 1999 to 2023.","volume":"4","author":"Ahmed","year":"2025","journal-title":"JACC Adv"},{"key":"R9-20260219","doi-asserted-by":"crossref","first-page":"e70132","DOI":"10.1002\/clc.70132","article-title":"Rising mortality related to diabetes mellitus and hypertension: trends and disparities in the United States (1999\u22122023).","volume":"48","author":"Hashmi","year":"2025","journal-title":"Clin Cardiol"},{"key":"R10-20260219","doi-asserted-by":"crossref","first-page":"102576","DOI":"10.1016\/j.jacadv.2025.102576","article-title":"Trends in mortality associated with ischemic heart disease and screenable cancers in the United States, 1999 to 2024.","volume":"5","author":"Rana","year":"2026","journal-title":"JACC Adv"},{"key":"R11-20260219","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults.","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet"},{"key":"R12-20260219","doi-asserted-by":"crossref","first-page":"e70126","DOI":"10.1002\/edm2.70126","article-title":"Once-weekly insulin efsitora alfa versus once daily insulin in patients with Type 2 diabetes: a systematic review and meta-analysis.","volume":"8","author":"Mehmood","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"R13-20260219","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.15077","article-title":"New insights into the treatment of obesity.","volume":"25","author":"Bl\u00fcher","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R14-20260219","doi-asserted-by":"crossref","first-page":"e70127","DOI":"10.1111\/cts.70127","article-title":"Once-weekly semaglutide versus once-daily liraglutide for weight loss in adults: a meta-analysis of randomized controlled trials.","volume":"18","author":"Hashmi","year":"2025","journal-title":"Clin Transl Sci"},{"key":"R15-20260219","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/phar.4607","article-title":"Incretin hormone agonists: current and emerging pharmacotherapy for obesity management.","volume":"44","author":"Alhomoud","year":"2024","journal-title":"Pharmacotherapy"},{"key":"R16-20260219","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","article-title":"GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.","volume":"6","author":"Holst","year":"2024","journal-title":"Nat Metab"},{"key":"R17-20260219","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial.","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"R18-20260219","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight.","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"key":"R19-20260219","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.molmet.2013.12.001","article-title":"Action and therapeutic potential of oxyntomodulin.","volume":"3","author":"Pocai","year":"2014","journal-title":"Mol Metab"},{"key":"R20-20260219","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R21-20260219","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R22-20260219","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"R23-20260219","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R24-20260219","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R25-20260219","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.","volume":"53","author":"Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"R26-20260219","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"R27-20260219","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"R28-20260219","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"R29-20260219","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"R30-20260219","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"R31-20260219","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R32-20260219","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial.","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"R33-20260219","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"R34-20260219","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art.","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"R35-20260219","doi-asserted-by":"crossref","first-page":"e70234","DOI":"10.1002\/clc.70234","article-title":"GLP-1 and Dual GLP-1\/GIP receptor agonists in heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.","volume":"48","author":"Ahmed","year":"2025","journal-title":"Clin Cardiol"},{"key":"R36-20260219","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.2023.13872","article-title":"Patents and regulatory exclusivities on GLP-1 receptor agonists.","volume":"330","author":"Alhiary","year":"2023","journal-title":"JAMA"},{"key":"R37-20260219","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.amjmed.2025.09.019","article-title":"Oral anticoagulant monotherapy in patients with chronic coronary disease: an updated meta-analysis.","volume":"139","author":"Ahmed","year":"2025","journal-title":"Am J Med"},{"key":"R38-20260219","doi-asserted-by":"crossref","first-page":"102782","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R39-20260219","doi-asserted-by":"crossref","first-page":"2484048","DOI":"10.1080\/20018525.2025.2484048","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.","volume":"12","author":"Altobaishat","year":"2025","journal-title":"Eur Clin Respir J"},{"key":"R40-20260219","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials.","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"R41-20260219","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"R42-20260219","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"R43-20260219","first-page":"668","article-title":"The efficacy and safety of tirzepatide in patients with diabetes and\/or obesity: systematic review and meta-analysis of randomized clinical trials.","volume":"18","author":"Liu","year":"2025","journal-title":"Pharm Basel Switz"},{"key":"R44-20260219","doi-asserted-by":"crossref","first-page":"156038","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.","volume":"161","author":"Xie","year":"2024","journal-title":"Metabolism"},{"key":"R45-20260219","doi-asserted-by":"crossref","first-page":"e13717","DOI":"10.1111\/obr.13717","article-title":"Potent incretin-based therapy for obesity: a systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.","volume":"25","author":"M\u00fcllertz","year":"2024","journal-title":"Obes Rev"},{"key":"R46-20260219","first-page":"01615","article-title":"Glucagon-like peptide-1 receptor agonist use and outcomes in peripartum cardiomyopathy: a propensity-score matched analysis.","volume":"S0828-282X","author":"Jain","year":"2025","journal-title":"Can J Cardiol"},{"key":"R47-20260219","doi-asserted-by":"crossref","first-page":"3442754","DOI":"10.1155\/jobe\/3442754","article-title":"weight loss efficacy of tirzepatide compared to placebo or GLP-1 receptor agonists in adults with obesity or overweight: a meta-analysis of randomized controlled trials with \u2265 20 weeks treatment duration.","volume":"2025","author":"Khawaji","year":"2025","journal-title":"J Obes"},{"key":"R48-20260219","doi-asserted-by":"crossref","first-page":"1593134","DOI":"10.3389\/fendo.2025.1593134","article-title":"Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.","volume":"16","author":"Tian","year":"2025","journal-title":"Front Endocrinol"},{"key":"R49-20260219","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1871529X11202020113","article-title":"A review of obesity and body fat distribution and its relationship to cardio-metabolic risk in men and women of Chinese origin.","volume":"12","author":"Lear","year":"2012","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"R50-20260219","first-page":"e56939","article-title":"Evaluating the efficacy and safety of tirzepatide on glycaemic and non-glycaemic outcomes in diabetes: a systematic review of meta-analyses.","volume":"16","author":"Kaore","year":"2024","journal-title":"Cureus"},{"key":"R51-20260219","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/08998280.2025.2456441","article-title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.","volume":"38","author":"Abdrabou Abouelmagd","journal-title":"Proc Bayl Univ Med Cent"},{"key":"R52-20260219","doi-asserted-by":"crossref","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol"},{"key":"R53-20260219","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R54-20260219","doi-asserted-by":"crossref","first-page":"26335565251370816","DOI":"10.1177\/26335565251370816","article-title":"Trends and disparities in heart failure and heart failure with obesity mortality among U.S. adults: A 1999-2020 analysis of geographic, gender, and racial variations using CDC WONDER data.","volume":"15","author":"Ahmed","year":"2025","journal-title":"J Multimorb Comorb"},{"key":"R55-20260219","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"R56-20260219","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective.","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R57-20260219","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1210\/clinem\/dgae319","article-title":"Effects of tirzepatide vs semaglutide on \u03b2-cell function, insulin sensitivity, and glucose control during a meal test.","volume":"109","author":"Mather","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-20260219","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.","volume":"47","author":"Tan","year":"2023","journal-title":"Int J Obes (Lond)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:00:16Z","timestamp":1771513216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001209","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}